Key result
A model incorporating plasma mRNA levels and eQTLs achieved a 77% area under the curve to discriminate Alzheimer's disease from controls, an 8% improvement over a baseline clinical model.
Why the study?
The study focused on identifying genetic risk factors and novel plasma biomarkers for Alzheimer's disease.
Does incorporating plasma mRNA levels improve the predictive value of Alzheimer's disease biomarker panels in African Americans?
Case-Control (n=420)
Does incorporating plasma mRNA levels improve the predictive value of Alzheimer's disease biomarker panels in African Americans?
Incorporating plasma mRNA levels of AD-relevant genes improves the predictive value of Alzheimer's disease biomarker panels in African Americans.
Answers are grounded in this paper and cite their sources.
May enhance AD discrimination in African Americans; leaves open prospective validation before clinical use.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2022) conducted a case-control in Alzheimer's disease (n=420). Plasma mRNA levels of AD-relevant genes vs. Clinical model (age, sex, APOE-ε4 dosage) was evaluated on Discrimination of AD vs. CU (Area under the curve) (AUC 77%). A model incorporating plasma mRNA levels and eQTLs achieved a 77% area under the curve to discriminate Alzheimer's disease from controls, an 8% improvement over a baseline clinical model.
Synapse has enriched 10 related papers. Consider them for comparative context: